Trial Profile
A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ROS1-rearranged Non-squamous Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 25 Dec 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2024.
- 01 Mar 2022 Planned End Date changed from 1 Jun 2021 to 1 Dec 2023.